P2376 - Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia

Monday, October 23, 2023

10:30 AM – 4:15 PM PT

Location: Exhibit Hall

Has Audio

Presenting Author(s)

Valeriya O. Zaborska, BSc, MD

UBC
Vancouver, BC, Canada

Valeriya O. Zaborska, BSc, MD¹, Alnoor Ramji, MD², Hin Hin Ko, MD, FRCPC³, Edward Tam, MD⁴
¹UBC, Vancouver, BC, Canada; ²Gastrointestinal Research Institute, Vancouver, BC, Canada; ³University of British Columbia, Vancouver, BC, Canada; ⁴Pacific Gastroenterology Associates, Vancouver, BC, Canada

Introduction: Globally, HDV is reported in 4.5-13% of chronic hepatitis B (CHB) patients. HDV and HBV co-infection is associated with progression to cirrhosis and higher risk of hepatocellular carcinoma (HCC). HDV prevalence in Canada is not fully elucidated. The purpose of the study was to describe the prevalence and clinical characteristics of HDV infection in CHB patients in a tertiary care centre.

Methods: Retrospective study of HBsAg-positive patients >18 years of age tested for HDV Ab between April 2013 and October 2022. Data collected included HDV Ab status, patient demographics, comorbidities, alcohol use, fibrosis stage, and therapies utilized.

Results: Among 663 HBsAg-positive patients tested for HDV Ab,10/663 (1.5%, 95% CI 0.58-2.44) were HDV-Ab (+), with 8/10 (80%, 95% CI 0.55-1.05) of those confirmed HDV RNA(+). Average age of HDV patients was 57.8 (95% CI 52.7- 62.9) years, similar to HBV patients. Compared to HBV mono-infected patients, HBV-HDV co-infected patients were more likely to be male (90.0% vs 57.6%; p=0.04), have decompensated liver disease (30.0% vs 1.4%; p< 0.0001) and less likely to be Asian (50.0% vs 80.9%; p =0.014). One HBV-HDV co-infected patient was also HIV/HCV co-infected, and two had cleared HCV. One HDV patient had a known history of IVDU (10%, 95% CI 0.09 – 0.28). Mean ALT in HDV patients was 55.9, vs. 34.3 in HBV mono group (p=0.0508). 50% of HDV patients consumed any lifetime alcohol compared to 31.9% of HBV mono-infected patients (p=0.22). HDV patients were more likely to have liver stiffness measurements >9.0 kPa 30% vs 8.9%, p=0.02), and equally likely to have HCC 10% vs 2.5% (p=0.13).

Discussion: The prevalence of HDV positivity in CHB patients in this tertiary care centre was 1.5%. This was less than a previously noted 4.8% prevalence of HDV positivity amongst HBsAg-positive patients enrolled in in the Canadian HBV Network between 2011-2019. Persons with HDV were more likely to be male, and have decompensated liver disease and less likely to be Asian than those with HBV mono-infection. Further studies to understand the burden of disease in other regions are needed.

Disclosures:

Valeriya Zaborska indicated no relevant financial relationships.

Alnoor Ramji: Abbvie – Advisor or Review Panel Member, Grant/Research Support, Speakers Bureau. Amgen – Speakers Bureau. Gilead – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Intercept – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Janssen – Grant/Research Support. Novartis – Grant/Research Support. Novo-Nordisc – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Pfizer – Grant/Research Support.

Hin Hin Ko: AbbVie – Advisory Committee/Board Member, Consultant, Clinical Investigator, Speakers Bureau. Celgene – Clinical Investigator. Escient – Clinical Investigator. Gilead – Advisory Committee/Board Member, Consultant, Clinical Investigator, Speakers Bureau. Intercept – Advisory Committee/Board Member, Consultant, Clinical Investigator, Speakers Bureau. Ipsen – Advisory Committee/Board Member, Consultant, Clinical Investigator. Lupin – Advisory Committee/Board Member, Consultant, Speakers Bureau. Madrigal – Clinical Investigator. Merck – Advisory Committee/Board Member, Consultant, Clinical Investigator, Speakers Bureau. Pilant – Clinical Investigator. Sanofi – Advisory Committee/Board Member, Consultant, Clinical Investigator, Speakers Bureau.

Edward Tam: Abbvie – Advisor or Review Panel Member, Advisory Committee/Board Member, Speakers Bureau. Advanz Pharma – Consultant, Speakers Bureau. Gilead – Advisor or Review Panel Member, Advisory Committee/Board Member, Speakers Bureau. Intercept – Advisor or Review Panel Member, Advisory Committee/Board Member, Speakers Bureau.

Valeriya O. Zaborska, BSc, MD¹, Alnoor Ramji, MD², Hin Hin Ko, MD, FRCPC³, Edward Tam, MD⁴. P2376 - Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.